Baird Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $57
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
Baird analyst Jack Allen initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $57.
Baird analyst Jack Allen initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $57.